Salarius Pharmaceuticals Inc. (SLRX) is a clinical-stage biotechnology company headquartered in Houston, Texas, specializing in the development of innovative epigenetic therapies targeting cancer. With a strong commitment to addressing unmet medical needs, Salarius aims to advance its promising pipeline of treatments that leverage the unique mechanisms of epigenetics to improve outcomes for patients battling various malignancies. The company is dedicated to advancing its research through rigorous clinical trials, with a focus on transforming cancer care and enhancing therapeutic effectiveness.